Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Thoracic 5CNS 5Genitourinary 3Gastrointestinal 3Dermatologic 3Breast 3Plasma cell 2Myeloid 2Lymphoid 2Gynecologic 2Classical hematology 2Tumor-Agnostic 1Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Mouth Neoplasms 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Tretinoin × Head & Neck × Clear all
NCT06728631 2025-02-24

Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Active not recruiting
22 enrolled
Head & Neck

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡